NCT07343518

Brief Summary

Considering the promising effects observed and the scarce and incipient scientific background of SFN in sports, the present study aims to evaluate the effects of SFN supplementation on fatigue, EIMD and recovery in trained individuals. In particular, outcomes such as time to exhaustion (TTE), and perceptual questionnaires of muscle soreness, recovery, and fatigue will be assessed, aiming to explore the effectiveness of SFN.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2026

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 20, 2025

Completed
13 days until next milestone

Study Start

First participant enrolled

January 2, 2026

Completed
13 days until next milestone

First Posted

Study publicly available on registry

January 15, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

January 15, 2026

Status Verified

January 1, 2026

Enrollment Period

3 months

First QC Date

December 20, 2025

Last Update Submit

January 6, 2026

Conditions

NutritionSports

Keywords

sulforaphanefatigueathletic performance

Outcome Measures

Primary Outcomes (1)

  • time to exhaustion

    24 hours

Secondary Outcomes (4)

  • Rating of Fatigue Scale

    Baseline, 30 minutes, 24 hours

  • Total Quality Recovery Scale

    Baseline, 30 minutes, 24 hours

  • Muscle soreness (Visual analogue scale)

    Baseline, 30 minutes, 24 hours

  • Rating of perceived exertion scale

    30 minutes

Study Arms (2)

Sulforaphane

EXPERIMENTAL

Sulforaphane supplementation (Nomio)

Other: Fatigue protocol

Placebo

PLACEBO COMPARATOR

Placebo intervention

Other: Fatigue protocol

Interventions

Fatigue protocolOTHER

Fatigue protocol comprising 6 sets of 30 seconds at 120% of velocity of maximal oxygen consumption

PlaceboSulforaphane

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Physically active individuals (engaging in exercise 3 or more times per week)

You may not qualify if:

  • Individuals that experience musculoskeletal injuries or have experienced in the past 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Fatigue

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Both participants and investigator will be blinded to the experimental conditions. Both placebo and supplementation will have the same appearence. Only the outcome assessor will know the assigned sequence to each participant
Purpose
OTHER
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 20, 2025

First Posted

January 15, 2026

Study Start

January 2, 2026

Primary Completion

April 1, 2026

Study Completion

May 1, 2026

Last Updated

January 15, 2026

Record last verified: 2026-01